In this issue:
Recommendations for transplantation and cellular therapies in myeloma
Most alloSCT recipients respond to COVID vaccination
Reduced-intensity conditioned alloSCT for older ALL
Survival and GvHD with haploidentical vs other allogeneic grafts for ALL
Prognostic value of day 100 score for GvHD and TRM after alloSCT
Synergistic high-dose chemotherapy regimens have improved HL outcomes
Survival of relapsed/refractory classical HL patients in the era of novel agents
Peripheral blood parameter abnormalities precede t-MN after ASCT for lymphoma
Please login below to download this issue (PDF)